Login / Signup

[Repeated haploidentical allogeneic hematopoietic stem cell transplantation with TCR αβ/CD19 depletion in patient with primary myelofibrosis. Case report].

E I KolgaevaV A VasilyevaLarisa A KuzminaMikhail Yu DrokovMaria NareykoZ V KonovaD I ChebotarevA M KovriginaD V KamelskihTatiana V GaponovaM A SokolovaI N SubortsevaA L MelikyanMikhail MaschanElena N ParovichnikovaS M Kulikov
Published in: Terapevticheskii arkhiv (2021)
Indications of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with primary myelofibrosis are intermediate-2 and high-risk group of DIPSS (Dynamic International Prognostic Scoring System), beginning of the disease in childhood. The other adverse factors affect engraftment and survival after allo-HSCT, example partialy matched donor. But the result of allo-HSCT from matched related donors and result of allo-HSCT from haploidentical donors are comparable. The method for haploidentical hematopoietic stem cell transplantation is T-cell-depletion. This is clinical case of T-cell-depleted haploidentical hematopoietic stem cell transplantation in patient with primary myelofibrosis, the diagnosis was established in childhood.
Keyphrases